MedTrace Logo

Extended Perioperative Administration of Fibrinolysis Inhibitors After Cardiac Surgery

NCT06493227 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1373

Last updated 2025-01-27

No results posted yet for this study

Summary

PRIORITY is a pragmatic, multi-center, cluster crossover trial that aims to evaluate whether implementing a policy of routine extended (intraoperative and 4 hour after transfer to ICU) use of fibrinolysis inhibitors leads to a decrease in post-operative blood transfusion compared to a policy that only involves intraoperative use.

Conditions

  • Thoracic Surgery
  • Heart Diseases
  • Fibrinolysis Shutdown

Interventions

OTHER

No routine fibrinolysis inhibitors after surgery

Tranexamic acid or epsilon-aminocaproic acid should be administered intravenously during surgery. The dosage and method of administration should be followed according to the routine practice of the participating site.

OTHER

Routine fibrinolysis inhibitors after surgery

During surgery, it is recommended to administer 70% of the routine dose of Tranexamic acid or epsilon-aminocaproic acid intravenously. Following the surgery, the remaining 30% of this dose should be administered as a continuous intravenous infusion over the course of the first 4 hours.

Sponsors & Collaborators

  • Saint Petersburg State University, Russia

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-01
Primary Completion
2025-12-30
Completion
2026-06-01

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06493227 on ClinicalTrials.gov